StockNews.AI

Picard / SynCardia Featured on the Cruxx of MedTech Podcast

StockNews.AI • 1 minute

TTCISRGABMD
High Materiality8/10

Information

TUCSON, Ariz., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard”...

Original source

AI Summary

Picard Medical has launched a podcast featuring discussions on their Total Artificial Heart and the upcoming Emperor device. This highlights their long-term vision to address significant market needs amid a donor heart shortage, potentially enhancing investor interest and driving growth in the near future.

Sentiment Rationale

Historical examples show that product innovations and unique market positions drive positive stock reactions, as seen with companies like Intuitive Surgical with da Vinci systems.

Trading Thesis

Buy PMI as momentum builds around innovative heart solutions; target 6-12 months.

Market-Moving

  • The podcast launch could generate increased interest in PMI's technology and stock.
  • Potential commercial opportunities may attract institutional investment.
  • Market reception of the next-gen Emperor device will influence future growth.
  • Picard's unique position in the FDA-approved heart market offers limited competition.

Key Facts

  • Picard Medical launches a podcast discussing their artificial heart technology.
  • Podcast focuses on the impact of the SynCardia Total Artificial Heart.
  • Management outlines plans for the next-gen Emperor device.
  • They emphasize a significant market opportunity due to donor heart shortage.
  • Picard's artificial heart is FDA-approved and widely used internationally.

Companies Mentioned

  • SynCardia Systems (N/A): Subsidiary making the first commercially available total artificial heart.

Corporate Developments

This fits within 'Corporate Developments' as it highlights Picard Medical's ongoing innovation efforts and communication strategies to position itself in the market. The unique nature of their product in a growing healthcare segment suggests potential for increased investor interest and market activity.

Picard Medical, Inc. Launches Cruxx to MedTech Podcast Highlighting Innovations in Heart Technology

TUCSON, Ariz., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) has officially launched its Cruxx to MedTech Podcast, a series that explores the groundbreaking advancements of the SynCardia Total Artificial Heart (STAH) and the next-generation fully implantable Emperor device. This initiative aims to provide valuable insights from both patients and management, illustrating the real-world implications of heart technology on individuals battling end-stage heart failure.

Podcast Content Overview

The inaugural episodes of the podcast are anchored by compelling patient survival stories, showcasing the positive effects of the STAH system. As the discussion unfolds, Patrick NJ Schnegelsberg, CEO of SynCardia Systems and Picard Medical, elaborates on the distinctive features of the STAH platform alongside its innovative Emperor system. Key points highlighted during the episodes include:

  • A clear differentiation of STAH from alternative heart failure treatments
  • The strategic vision to develop a viable replacement for heart transplants
  • Insights into the significant market opportunity owing to a global shortage of donor hearts

Availability of the Podcast

The Cruxx to MedTech Podcast is accessible for streaming and download on popular platforms including Apple Podcasts, Spotify, and Google Podcasts. Additionally, the podcast can be found directly on Cruxx’s official website at thisiscruxx.com.

About Cruxx

Cruxx is not just a podcast but also a medical technology search and capital advisory firm dedicated to placing MedTech pioneers in essential roles that enhance longevity. The firm focuses on crucial sectors such as:

  • Cardiovascular technology
  • Surgical robotics
  • Neurotechnology
  • Artificial intelligence and digital health

Cruxx collaborates with founders, executives, and investors to foster innovation and build leadership teams in the MedTech industry. For more detailed information, visit www.thisiscruxx.com.

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent organization of SynCardia Systems, LLC, headquartered in Tucson, Arizona. The company is recognized as the leader in total artificial heart technology, offering the only commercially available system for patients with end-stage heart failure. The SynCardia Total Artificial Heart (STAH) is notable for being the first artificial heart to receive approval from both the FDA and Health Canada, and it remains the only such device authorized for use in the United States and Canada.

As of now, more than 2,100 implants have been performed in hospitals across 27 countries, making the STAH the most widely utilized and rigorously studied artificial heart globally. For further insights about Picard Medical, visit www.picardmedical.com or review the company's filings with the Securities and Exchange Commission at www.sec.gov.

Forward-Looking Statements

This announcement contains forward-looking statements that are subject to various risks and uncertainties. Such statements, which differ significantly from historical facts, may impact actual outcomes. Picard Medical disclaims any obligations to publicly update or revise these statements based on changes in circumstances or expectations. For more information regarding risks and uncertainties, refer to the Risk Factors section of the company's Registration Statement and related prospectus available on the SEC’s website.

Contact Information

For investor inquiries, contact:

Related News